Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis
Liming Zheng1,2, Zaikai Zhuang1,2, Yixuan Li1,2
1State Key Laboratory of Pharmaceutical Biotechnology, Division of Sports Medicine and Adult Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, PR China.
Bioactive Materials
|March 21, 2022
Summary
Iron oxide nanoparticles (IONPs) treat osteoporosis by reducing oxidative stress and promoting bone metabolism. Combined with alendronate, IONPs effectively target bone tissue, improving therapeutic outcomes in osteoporosis models.
Area of Science:
- Biomedical Engineering
- Orthopedics
- Nanotechnology
Background:
- Osteoporosis is a prevalent orthopedic disease in the elderly.
- Therapeutic strategies are shifting towards modulating local bone immunity to enhance bone metabolism.
- Previous research indicated iron oxide nanoparticles (IONPs) positively regulate bone metabolism in vitro.
Purpose of the Study:
- To investigate the in vivo therapeutic efficacy of IONPs in estrogen deficiency-induced osteoporosis.
- To evaluate the effect of IONPs on osteogenic and osteoclast differentiation.
- To assess the synergistic therapeutic role of alendronate-delivered IONPs for bone targeting.
Main Methods:
- Daily administration of IONPs in an in vivo osteoporosis model.
- Assessment of reactive oxygen species scavenging activity.
- Evaluation of osteogenic differentiation of bone marrow mesenchymal stem cells and osteoclast differentiation of monocytes.
- Combination therapy using alendronate for targeted delivery of IONPs to bone tissue.
- Verification of bone targeting, therapeutic efficiency, and biocompatibility in ovariectomy-induced osteoporotic mice.
Main Results:
- Daily IONP administration alleviated osteoporosis in mice by scavenging reactive oxygen species.
- IONPs promoted osteogenic differentiation and inhibited osteoclast differentiation.
- Alendronate-conjugated IONPs demonstrated synergistic therapeutic effects and bone targeting capabilities.
- The novel bone-targeting nanoparticles (BTNPs) significantly revised ovariectomy-induced osteoporosis by positively regulating bone metabolism.
Conclusions:
- IONPs are effective in treating osteoporosis in vivo by modulating bone metabolism and reducing oxidative stress.
- Alendronate-mediated delivery enhances the bone targeting and therapeutic efficiency of IONPs.
- BTNPs represent a promising therapeutic approach for osteoporosis with significant potential for clinical application.
Related Concept Videos
01:31Essential Minerals for Bone Health
4.6K
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
4.6K
01:25Role of Vitamins in Maintaining Bone Health
3.8K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.8K
01:29Bone Disorders
4.1K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.1K
01:28Menopause
596
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
596